000130573 001__ 130573
000130573 005__ 20240228143445.0
000130573 0247_ $$2doi$$a10.1038/bjc.2016.104
000130573 0247_ $$2pmid$$apmid:27115465
000130573 0247_ $$2pmc$$apmc:PMC4865967
000130573 0247_ $$2ISSN$$a0007-0920
000130573 0247_ $$2ISSN$$a1532-1827
000130573 037__ $$aDKFZ-2017-05652
000130573 041__ $$aeng
000130573 082__ $$a610
000130573 1001_ $$aSjöberg, Elin$$b0
000130573 245__ $$aExpression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer.
000130573 260__ $$aEdinburgh$$bNature Publ. Group$$c2016
000130573 3367_ $$2DRIVER$$aarticle
000130573 3367_ $$2DataCite$$aOutput Types/Journal article
000130573 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521188740_1657
000130573 3367_ $$2BibTeX$$aARTICLE
000130573 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130573 3367_ $$00$$2EndNote$$aJournal Article
000130573 520__ $$aExpression of the chemokine CXCL14 has previously been shown to be elevated in the tumour stroma of, for example, prostate and breast cancer. Cancer-associated fibroblast-derived CXCL14 enhances tumour growth in mouse models of prostate and breast cancer. However, the prognostic significance of compartment-specific expression of CXCL14 has not been studied.CXCL14 mRNA expression was analysed in a breast cancer tissue microarray (TMA) of formalin-fixed, paraffin-embedded tumours by the RNAscope 2.0 Assay. Epithelial and stromal expression was analysed separately and correlated with clinicopathological characteristics and survival.CXCL14 was variably and independently expressed in malignant and stromal cells of breast cancer. Total and stromal expression of CXCL14 did not associate with clinicopathological parameters. Epithelial CXCL14 expression was significantly associated with oestrogen receptor α (ERα)-positive tumours and lower proliferation status. Total CXCL14 expression correlated significantly with shorter breast cancer-specific and recurrence-free survival. High stromal, but not epithelial, CXCL14 expression was significantly associated with shorter survival in univariable and multivariable analyses. Moreover, the correlation between stromal CXCL14 expression and survival was more prominent in ER negative, triple negative and basal-like breast cancers.The identification of prognostic significance of stromal CXCL14 in breast cancer demonstrates novel clinical relevance of a stroma-derived secreted factor and illustrates the importance of tumour compartment-specific analyses. On the basis of the prognostic signals from difficult-to-treat subgroups, CXCL14 should also be considered as a candidate drug target.
000130573 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000130573 588__ $$aDataset connected to CrossRef, PubMed,
000130573 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000130573 650_7 $$2NLM Chemicals$$aCXCL14 protein, human
000130573 650_7 $$2NLM Chemicals$$aChemokines, CXC
000130573 7001_ $$0P:(DE-He78)d05f6ed88b416dda3e27a7efe899b53f$$aAugsten, Martin$$b1$$udkfz
000130573 7001_ $$aBergh, Jonas$$b2
000130573 7001_ $$aJirström, Karin$$b3
000130573 7001_ $$aÖstman, Arne$$b4
000130573 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/bjc.2016.104$$gVol. 114, no. 10, p. 1117 - 1124$$n10$$p1117 - 1124$$tBritish journal of cancer$$v114$$x1532-1827$$y2016
000130573 909CO $$ooai:inrepo02.dkfz.de:130573$$pVDB
000130573 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d05f6ed88b416dda3e27a7efe899b53f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130573 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000130573 9141_ $$y2016
000130573 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2015
000130573 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130573 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130573 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130573 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130573 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130573 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130573 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130573 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130573 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130573 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130573 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130573 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130573 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2015
000130573 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lVaskuläre Onkologie und Metastasierung$$x0
000130573 980__ $$ajournal
000130573 980__ $$aVDB
000130573 980__ $$aI:(DE-He78)A190-20160331
000130573 980__ $$aUNRESTRICTED